Adelaide Research & Scholarship: Search

Search

Results 1-10 of 12 (Search time: 0.001 seconds).

previous
1
2
next

Item hits:

Preview	Issue Date	Title	Author(s)
	2018	Long-term treatment-free remission of chronic myeloid leukemia with falling levels of residual leukemic cells	Ross, D.; Pagani, I.; Shanmuganathan, N.; Kok, C.; Seymour, J.; Mills, A.; Filshie, R.; Arthur, C.; Dang, P.; Saunders, V.; Braley, J.; Yong, A.; Yeung, D.; White, D.; Grigg, A.; Schwarer, A.; Branford, S.; Hughes, T.
	2012	Contrasting effects of diclofenac and ibuprofen on active imatinib uptake into leukaemic cells	Wang, J.; Hughes, T.; Kok, C.; Saunders, V.; Frede, A.; Groot Obbink, K.; Osborn, M.; Somogyi, A.; D'Andrea, R.; White, D.
	2013	Proton pump inhibitors significantly increase the intracellular concentration of nilotinib, but not imatinib in target CML cells	White, D.; Eadie, L.; Saunders, V.; Hiwase, D.; Hughes, T.
	2010	Nilotinib-mediated inhibition of ABCB1 increases intracellular concentration of dasatinib in CML cells: implications for combination TKI therapy	Hiwase, D.; White, D.; Zrim, S.; Saunders, V.; Vaz de Melo, J.; Hughes, T.
	2010	Chronic Myeloid Leukemia CD34+ cells have reduced uptake of imatinib due to low OCT-1 Activity	Engler, J.; Frede, A.; Saunders, V.; Zannettino, A.; Hughes, T.; White, D.
	2010	Blocking cytokine signaling along with intense Bcr-Abl kinase inhibition induces apoptosis in primary CML progenitors	Hiwase, D.; White, D.; Powell, J.; Saunders, V.; Zrim, S.; Frede, A.; Guthridge, M.; Lopez, A.; D'Andrea, R.; To, L.; Vaz de Melo, J.; Kumar, S.; Hughes, T.
	2010	The poor response to imatinib observed in CML patients with low OCT-1 activity is not attributable to lower uptake of imatinib into their CD34⁺ cells	Engler, J.; Frede, A.; Saunders, V.; Zannettino, A.; White, D.; Hughes, T.
	2010	Functional activity of the OCT-1 protein is predictive of long-term outcome in patients with chronic-phase chronic myeloid leukemia treated with Imatinib	White, D.; Dang, P.; Engler, J.; Frede, A.; Osborn, M.; Saunders, V.; Manley, P.; Zrim, S.; Hughes, T.
	2013	Dasatinib targets chronic myeloid leukemia-CD34⁺ progenitors as effectively as it targets mature cells	Hiwase, D.; Saunders, V.; Nievergall, E.; Ross, D.; White, D.; Hughes, T.
	2012	Chronic phase chronic myeloid leukemia patients with low OCT-1 activity randomized to high-dose imatinib achieve better responses and have lower failure rates than those randomized to standard-dose imatinib	White, D.; Radich, J.; Soverini, S.; Saunders, V.; Frede, A.; Dang, P.; Cilloni, D.; Lin, P.; Mongay, L.; Woodman, R.; Manley, P.; Slader, C.; Kim, D.; Pane, F.; Martinelli, G.; Saglio, G.; Hughes, T.